Please login to the form below

Not currently logged in
Email:
Password:

EUSA founder joins Oxford BioTherapeutics as chairman

Bryan Morton has rich experience in oncology

Oxford Biotherapeutics Bryan MortonOncology-focused biotech Oxford BioTherapeutics has appointed industry veteran Bryan Morton as non-executive chairman.

Morton has 30 years' experience in the life sciences industry, including founding and serving as CEO of oncology specialist EUSA Pharma. This company was later sold to Jazz Pharma in 2012 for $700m.

Prior to founding EUSA in 2005, Morton founded Zeneus Pharma in 2003, before selling the company to Cephalon for $360m.

In addition to his entrepreneurial activities, Morton served as president of Convatec EMEA and spent more than 20 years in various roles at Merck & Co.

“His success in building valuable businesses and knowledge of the cancer space in particular will be important as we look to further develop our pipeline of antibody based cancer medicines to fulfil unmet patient needs,” said Christian Rohlff, CEO and founder of Oxford BioTherapeutics.

28th June 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

AI and genomics: a revolution in drug discovery and development
...
Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....

Infographics